{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=San+Antonio&page=8&state=Texas",
    "query": {
      "state": "Texas",
      "city": "San Antonio",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 3151,
    "total_pages": 316,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=San+Antonio&page=9&state=Texas&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=San+Antonio&page=7&state=Texas&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T12:32:07.839Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04194437",
      "title": "OCS Liver DCD Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Liver Transplant"
      ],
      "interventions": [
        {
          "name": "OCS Liver System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "TransMedics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-07-24",
      "completion_date": "2024-12-16",
      "has_results": true,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-11-02T12:32:07.839Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04194437"
    },
    {
      "nct_id": "NCT01722188",
      "title": "Lead Registry for Optim Leads",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Optim Lead Insulation Related Adverse Events"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14124,
      "start_date": "2006-08",
      "completion_date": "2020-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-11-02T12:32:07.839Z",
      "location_count": 245,
      "location_summary": "Alabaster, Alabama • Fort Payne, Alabama • Gadsden, Alabama + 189 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Fort Payne",
          "state": "Alabama"
        },
        {
          "city": "Gadsden",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01722188"
    },
    {
      "nct_id": "NCT02919761",
      "title": "Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "Acthar Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 259,
      "start_date": "2016-11-07",
      "completion_date": "2019-02-13",
      "has_results": true,
      "last_update_posted_date": "2020-03-31",
      "last_synced_at": "2026-11-02T12:32:07.839Z",
      "location_count": 30,
      "location_summary": "San Leandro, California • Upland, California • Boynton Beach, Florida + 23 more",
      "locations": [
        {
          "city": "San Leandro",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02919761"
    },
    {
      "nct_id": "NCT02858076",
      "title": "Anti-VEGF vs. Prompt Vitrectomy for VH From PDR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Proliferative Diabetic Retinopathy",
        "Vitreous Hemorrhage"
      ],
      "interventions": [
        {
          "name": "2-mg Intravitreous Aflibercept Injection",
          "type": "DRUG"
        },
        {
          "name": "Prompt Vitrectomy Plus Panretinal Photocoagulation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2016-11",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2021-04-20",
      "last_synced_at": "2026-11-02T12:32:07.839Z",
      "location_count": 60,
      "location_summary": "Campbell, California • Glendale, California • Huntington Beach, California + 50 more",
      "locations": [
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Porterville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02858076"
    },
    {
      "nct_id": "NCT02611817",
      "title": "Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Vedolizumab SC 108 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Vedolizumab IV 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 644,
      "start_date": "2016-01-04",
      "completion_date": "2019-08-06",
      "has_results": true,
      "last_update_posted_date": "2022-05-25",
      "last_synced_at": "2026-11-02T12:32:07.839Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Middletown",
          "state": "Connecticut"
        },
        {
          "city": "Inverness",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02611817"
    },
    {
      "nct_id": "NCT01436968",
      "title": "Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Aglatimagene besadenovec + valacyclovir",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo + valacyclovir",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 711,
      "start_date": "2011-09",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-11-02T12:32:07.839Z",
      "location_count": 72,
      "location_summary": "Gilbert, Arizona • Glendale, Arizona • Peoria, Arizona + 56 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix, Mesa, Scottsdale, Sedona",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01436968"
    },
    {
      "nct_id": "NCT02189486",
      "title": "Prostate Cancer Upgrading Reference Set",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "35 Years to 99 Years · Male only"
      },
      "enrollment_count": 382,
      "start_date": "2014-08",
      "completion_date": "2025-06-16",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-11-02T12:32:07.839Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02189486"
    },
    {
      "nct_id": "NCT01429441",
      "title": "Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vitreomacular Adhesion Including Macular Hole"
      ],
      "interventions": [
        {
          "name": "Ocriplasmin",
          "type": "DRUG"
        },
        {
          "name": "Sham injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ThromboGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2011-10",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-03-14",
      "last_synced_at": "2026-11-02T12:32:07.839Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01429441"
    },
    {
      "nct_id": "NCT00985218",
      "title": "In Vitro Human Embryo Culture System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "SMART System",
          "type": "DEVICE"
        },
        {
          "name": "Culture dish",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Incept BioSystems, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 35 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2009-11",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2010-09-09",
      "last_synced_at": "2026-11-02T12:32:07.839Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Clearwater, Florida • Mt. Pleasant, South Carolina + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00985218"
    },
    {
      "nct_id": "NCT00317642",
      "title": "A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "clofarabine (IV formulation)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2006-08",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2014-04-14",
      "last_synced_at": "2026-11-02T12:32:07.839Z",
      "location_count": 41,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00317642"
    }
  ]
}